Descrizione del progetto
Una piattaforma innovativa per la diagnosi precoce dell’Alzheimer
Il morbo di Alzheimer (AD, Alzheimer’s Disease) è uno dei maggiori problemi che gli scienziati e i sistemi sanitari devono affrontare. Tale patologia colpisce milioni di persone e si prevede una crescita costante del numero di pazienti nel prossimo decennio. Una diagnosi precoce della malattia può impedirne la rapida evoluzione e consentire un’assistenza sanitaria accurata. Manca tuttavia un metodo così affidabile. Il progetto NORATEST, finanziato dall’UE, ha sviluppato una piattaforma innovativa in grado di rilevare precocemente le malattie neurodegenerative. Essa combina le «firme» dei biomarcatori tracciati nel sangue con un sofisticato algoritmo informatico che consente l’identificazione dell’AD o di altre malattie neurodegenerative nelle fasi iniziali. L’innovativa tecnologia è veloce, economica, precisa, altamente scalabile e flessibile. La piattaforma sarà commercializzata online nei mercati dell’UE e degli Stati Uniti.
Obiettivo
Alzheimer's disease (AD) is a major medical problem and is currently an issue of global general interest as the total number of people with dementia is projected to reach ~80M in 2030 and almost duplicating this number by 2050. The lack of an efficient and affordable solution in the AD's health care sector has motivated our company Alzohis to develop NORATEST, a very unique and innovative e-Health platform producing significant improvements, in terms of speed efficiency, in the detection of neurodegenerative diseases. By means of a novel combination of biomarkers “signatures” detectable in the blood with a state-of-the-art computer algorithm NORATEST can discriminate patients suffering AD from those healthy ones, as well as detecting other neurodegenerative diseases. Our prototype, currently at TRL6, is the first reliable non-invasive molecular diagnostic method able to detect the disease in the very early stages, offering several competitive and innovative advantages such as: Cost-effective novel technology, fast, accurate, early ddiagnosis, data privacy coupled to smart analytics, user-friendly and highly scalable and adaptable platform. Our business model is a pay-per-use combined model of charging per analysis and direct online sales. The global AD market shows great opportunities for us since it was worth €2.5 B in 2016 and is set to reach €12.6 B by 2026 (CAGR of 17.5%). Worldwide we expect a market growth in both established and in developing countries, anticipating >5M annual AD's diagnoses in the two main markets leaders based in Europe (2.5-3.5M diagnoses/year) and USA (1.5-2.5M diagnoses/year) by 2024. Our company goal is to become the reference for AD's diagnosis in Europe. We estimated that in 5 years (end of Phase 2 project), we will accumulate 360K diagnosis tests sales (revenue €54M) accounting for ~2% of the EU and USA market. We expect to hire 40 new technical and sales employees and earn ~€32M profit, with a ROI of 6.5.
Campo scientifico
Programma(i)
Argomento(i)
Invito a presentare proposte
Vedi altri progetti per questo bandoBando secondario
H2020-SMEInst-2018-2020-1
Meccanismo di finanziamento
SME-1 - SME instrument phase 1Coordinatore
91400 PARIS
Francia
L’organizzazione si è definita una PMI (piccola e media impresa) al momento della firma dell’accordo di sovvenzione.